PTCT, US69366J2006

PTC Therapeutics stock rises as third quarter data strengthen outlook

Published on 09/23/2026 at 15:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PTC Therapeutics stock traded at USD 140.00 on September 23, 2026, after a 3.5 percent rise. Third-quarter net new ARR reached USD 60 million.

PTCT, US69366J2006, Illustration mit AI erstellt.

PTC Therapeutics, Inc. (ISIN US69366J2006) traded at USD 140.00 on Nasdaq on September 23, 2026, after rising 3.5 percent during the session. The latest operating update points to USD 60 million in third-quarter net new annual recurring revenue, giving the stock a concrete growth metric beyond the daily price move.

ARR reaches USD 60 million

According to ChoiceStock on September 23, 2026, PTC reported USD 60 million in net new ARR for the third quarter and raised its annual guidance to 9.25 percent. The combination of an operating figure and updated guidance gives the market a more measurable basis for assessing execution.

The same report described the update as an investor conference centered on AI-based products JetStream and Orbit. It also noted that the presentation did not provide revenue, EPS, margin or other detailed earnings figures, so ARR and guidance remain the clearest quantified indicators in the current update.

Stock remains below yearly high

Market data placed PTC at USD 135.52 on Nasdaq at the September 22, 2026 close, up 0.18 percent on the session. The quote was USD 71.97 below the 52-week high of USD 207.49 and USD 27.02 above the 52-week low of USD 108.50, putting the stock 34.7 percent below its yearly high.

Trading volume was 277,595 shares on September 22, 2026, compared with an average volume of 1.45 million shares. The gap between the latest volume and the stated average shows that the price move occurred without unusually heavy turnover, while the USD 14.71 billion market capitalization leaves valuation and execution as the key market questions.

ARR and guidance set the checkpoint

The current comparison is therefore between USD 60 million of third-quarter net new ARR and the 9.25 percent annual guidance figure, not between a newly reported revenue number and an older baseline. For investors, the next material test is whether the AI product plans convert the operating momentum into the detailed revenue, earnings and margin data that were not included in the September 23 update.

Nasdaq price remains the reference

PTC Therapeutics traded at USD 140.00 on Nasdaq on September 23, 2026, following the reported 3.5 percent session gain. The September 22 close was USD 135.52, with the latest reported 52-week range extending from USD 108.50 to USD 207.49.